Recently, combining autophagy inhibitors with MEK inhibitors in treatment of CRC and pancreatic cancer has shown promise in vitro and is being studied further in anticipation of advancement to clinical trials [29–31]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.